Clinical trials: Depressive Disorder, Major
Treatment-resistant Depression
Slow Wave Induction by Propofol to Eliminate Depression (SWIPED) I
Our hypothesis is that targeted propofol infusion in treatment-resistant depressed patients will induce slow wave activity during sedation and augment subsequent sleep slow wave activity.
- Trial name
- NCT04680910
- Testing
- Propofol, Electroencephalography (EEG), Slow-Wave Activity
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Washington University School of Medicine
Major Depression, Dysthymia
Dichotic Listening as a Predictor of Medication Response in Depression
Depressed patients will have hearing tests and then be treated with up to three treatments (i.e., Fluoxetine, Imipramine) until remitted, to see whether test results predict specific outcomes.
- Conditions
- Major Depression, Dysthymia, Depressive Disorder Not Otherwise Specified
- Trial name
- NCT00296725
- Testing
- Fluoxetine, Imipramine
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
Long-Term Administration Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder
To examine the safety and efficacy of long term administration of aripiprazole as an adjunctive therapy, co-administered with either a selective serotonin reuptake inhibitor (SSRI) or a selective-norepinephrine reuptake inhibitor…
- Trial name
- NCT00882362
- Testing
- OPC-14597 (Aripiprazole)
- Where
- 8 sites in Japan
- Volunteers
- 155 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Major Depressive Disorder, Dysthymia
Dichotic Listening as a Predictor of Medication Response in Depression
This study will recruit 100 depressed patients to test whether the previous finding of an association between treatment response (with treatment groups including placebo, imipramine, and fluoxetine) and preferences of hemispheric…
- Trial name
- NCT00404755
- Testing
- escitalopram, bupropion, imipramine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- New York State Psychiatric Institute
Depression
Fevarin® Effectiveness in Treatment of Depression in Patients With Neurological Disorder
Prospective, multicenter, non-comparative, observational program to describe prevalence of depressive symptoms in a variety of neurological disorders and effects of Fevarin® on the severity of anxiety and depression, sleep state…
- Trial name
- FRIENDS (NCT02043197)
- Where
- 29 sites in Russia
- Volunteers
- 300 people
- Sponsor
- Abbott
Major Depressive Disorder
A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)
This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as a monotherapy for Major Depressive Disorder.
- Trial name
- Reliance III (NCT05081167)
- Testing
- REL-1017
- Where
- 10 sites in United States
- Volunteers
- 232 people
- Sponsor
- Relmada Therapeutics, Inc.
Major Depressive Disorder
Comparison of Behavioral Activation and Antidepressant Medication in the Treatment of Adolescents With Depression
This study focuses on treating adolescents with depression. The study has two main purposes. The first is to compare a new form of therapy for depression called Behavioral Activation (BA) to the antidepressant medication…
- Trial name
- NCT01740726
- Testing
- Behavioral Activation, Fluoxetine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Emory University
Depression
Role of Slow-wave Activity and Plasticity in MDD
The hypothesis underlying this proposal is that deficits of synaptic plasticity underlie the slow-wave activity (SWA) abnormalities observed n major depressive disorder (MDD), and that manipulating SWA may serve to circumvent…
- Trial name
- SWIP (NCT04150718)
- Testing
- slow-wave disruption
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Depression, Major Depressive Disorder
Nitrous Oxide as Treatment for Major Depression - a Pilot Study
Major depressive disorder (MDD) is a global medical problem with significant shortcomings in current therapy. Chief among these is the delay between initiation of pharmacologic therapy and clinical improvement in symptoms.
- Trial name
- NCT02139540
- Testing
- Nitrous Oxide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Washington University School of Medicine
Depression
Pre-Treatment Positron Emission Topography Scanning for Increasing Success in Antidepressant Treatment
This study will use pre-treatment positron emission topography and functional magnetic resonance imaging scans of the brain to predict the most effective antidepressant treatment for people with major depressive disorder.
- Trial name
- NCT00456014
- Testing
- Escitalopram, Desipramine
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- New York State Psychiatric Institute
Smoking Cessation, Cigarette Smoking
Treating Smokers With Mental Illness
This is a smoking cessation study that will enroll smokers who have been diagnosed with a severe mental illness. The study will use a combination of intensive tobacco treatment counseling and nicotine replacement therapy to…
- Conditions
- Smoking Cessation, Cigarette Smoking, Schizophrenia, Psychotic Disorders
- Trial name
- NCT03822416
- Testing
- Nicotine patch, Nicotine lozenge, Therapy
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Major Depressive Disorder
Mechanisms of Antidepressant Non-Response in Late-Life Depression
This project seeks to elucidate the mechanisms by which antidepressant medications have limited efficacy in Late Life Depression (LLD) in order to develop new treatment interventions for this prevalent and disabling illness.
- Trial name
- NCT01931202
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder, Cognitive Behavior Therapy
Using a Text-message System to Engage Depressed Adolescents in Cognitive-behavioral Therapy Homework
The primary goal of the pilot is to test the feasibility and utility of using a text-messaging system to engage adolescents in improved homework adherence during cognitive-behavioral therapy (CBT) for major depressive disorder.
- Conditions
- Major Depressive Disorder, Cognitive Behavior Therapy, Text Messaging
- Trial name
- NCT00919932
- Testing
- Paper and pen homework, Text message system homework.
- Volunteers
- 9 people
- Sponsor
- University of Pittsburgh
Major Depressive Disorder
A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder
The purpose of this study is to assess the effect and safety of AZD6765 in patients with major depressive disorder who exhibit inadequate response to antidepressants.
- Trial name
- NCT01482221
- Testing
- AZD6765 iv
- Where
- 44 sites in United States, Chile and 2 more
- Volunteers
- 542 people
- Sponsor
- AstraZeneca
Schizophrenia, Bipolar Disorder
Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis
The purpose of this study is to better understand mental illness and will test the hypotheses that, while viewing affective stimuli, patient groups will show increased blood oxygenation level dependent (BOLD) signal by fMRI after…
- Conditions
- Schizophrenia, Bipolar Disorder, Healthy, Psychosis
- Trial name
- GABAmech (NCT04004416)
- Testing
- Lorazepam and fMRI
- Where
- United States
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Major Depressive Disorder, Depression
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken together with another antidepressant.
- Trial name
- NCT01180400
- Testing
- TC-5214
- Where
- 66 sites in Czechia, Estonia and 8 more
- Volunteers
- 295 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
Supportive and Supportive-Expressive Treatment for Depression
This study will assign patients to two types of psychotherapies in treating people with a major depression disorder, expressive versus supportive techniques, and will examine their ability to benefit from treatment based on their…
- Trial name
- SSETD (NCT02728557)
- Testing
- Supportive-Expressive Therapy, Supportive Therapy
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- University of Haifa
Major Depressive Disorder
A Study of LY2216684 in Healthy Participants Receiving Albuterol or Propanolol
The purpose of this study is to determine the effect of LY2216684 on heart rate of participants receiving Albuterol and Propranolol. Information about any side effects that may occur will also be collected.
- Trial name
- NCT01263197
- Testing
- LY2216684, albuterol, propranolol
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Major
A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
The purpose of this study is to assess the efficacy of flexibly dosed JNJ-42847922 (20 milligram [mg] or 40 mg) compared to flexibly dosed quetiapine extended-release (XR) (150 mg or 300 mg) as adjunctive therapy to an…
- Trial name
- NCT03321526
- Testing
- JNJ-42847922, Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI)
- Where
- 50 sites in United States
- Volunteers
- 107 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Major
Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDD
This study will assess the safety, tolerability and efficacy of desvenlafaxine succinate sustained release (DVS SR) in subjects with major depressive disorder.
- Trial name
- NCT00445679
- Testing
- DVS SR, Paroxetine
- Where
- 43 sites in China, India and 2 more
- Volunteers
- 807 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer